ELUCIDATE FFRct Study
NCT: NCT06018194 · COMPLETED
NCT IDNCT06018194
StatusCOMPLETED
Start Date2023-09-01
Completion2025-07-28
SponsorElucid Bioimaging Inc. (INDUSTRY)
First posted
Last updated
Brief Summary
The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR). Researchers will compare the Elucid plaque-based FFRct analysis to invasively measured FFR in patients who have previously undergone CCTA and invasively assessed FFR.
Frequently Asked Questions
What is ELUCIDATE FFRct Study?
ELUCIDATE FFRct Study is a clinical trial registered under NCT06018194. Current status: COMPLETED.
What is the status of NCT06018194?
The current status of NCT06018194 (ELUCIDATE FFRct Study) is: COMPLETED.
When did ELUCIDATE FFRct Study start?
ELUCIDATE FFRct Study started on 2023-09-01.
Related Devices
K163071vascuCAPElucid Bioimaging, Inc.
K183012vascuCAPElucid Bioimaging, Inc.
K221463ElucidVivo A.3Elucid Bioimaging, Inc.
K241524Elucid PlaqueIQElucid Bioimaging, Inc.
K243881HeartSee™ Cardiac P.E.T. Processing Software For Myocardial Perfusion and Coronary Flow Reserve (CFR) Version 4Bracco Diagnostics, Inc.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.